Abstract: The present invention is based, in part, on the discovery of anti-VSIG4 composition (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-VSIG4 compositions for therapeutic, diagnostic, prognostic, and screening purposes.

Abstract: The present invention is based, in part, on the discovery of anti-PSGL-1 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof) that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-PSGL-1 compositions for therapeutic, diagnostic, prognostic, and screening purposes.

Abstract: The present invention is based, in part, on the discovery of anti-SIGLEC-9 composition (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-SIGLEC-9 compositions for therapeutic, diagnostic, prognostic, and screening purposes.

Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.

Abstract: The present invention is based, in part, on the discovery of anti-CD53 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate inflammatory phenotypes of myeloid cells, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-CD53 compositions for therapeutic, diagnostic, prognostic, and screening purposes.

Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Abstract: The present invention is based, in part, on the identification of compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof.

Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.

Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Abstract: Provided herein are embodiments relating to therapeutic applications of antibodies that modulate; e.g., inhibit the interaction of TIM-3 and LILRB2 antibodies. In some embodiments, the antibodies bind TIM-3. In some embodiments the antibodies bind LILRB2. Modulation of the interaction of TIM-3 and LILRB2 stimulates the release of pro-inflammatory cytokines; e.g., myeloid-associated pro-inflammatory cytokines.

Abstract: Systems for removing or attenuating friction and/or click noise generated during writing with a smart pen are disclosed. In a smart pen, the writing cartridge is biased towards a first side of the smart pen internal cavity by a low-force biasing system without affecting writing cartridge movement. For example, the writing cartridge is comprised of a magnetic material and a magnet is embedded into the first side of the smart pen internal cavity to bias the writing cartridge towards the first side. Alternatively, the material comprising the writing cartridge or smart pen internal cavity is modified, reducing friction between the components. As another alternative, a DSP method identifies analyzes one or more parameters of received audio data to differentiate click noise from audio data, and may receive data from a movement sensor indicating when the writing cartridge has moved to reduce power consumption for identifying click noise.

Abstract: Systems for removing or attenuating friction and/or click noise generated during writing with a smart pen are disclosed. In a smart pen, the writing cartridge is biased towards a first side of the smart pen internal cavity by a low-force biasing system without affecting writing cartridge movement. For example, the writing cartridge is comprised of a magnetic material and a magnet is embedded into the first side of the smart pen internal cavity to bias the writing cartridge towards the first side. Alternatively, the material comprising the writing cartridge or smart pen internal cavity is modified, reducing friction between the components. As another alternative, a DSP method identifies analyzes one or more parameters of received audio data to differentiate click noise from audio data, and may receive data from a movement sensor indicating when the writing cartridge has moved to reduce power consumption for identifying click noise.